Mativ Holdings heads into the final week of August with one of the more striking monthly price moves in its recent history — a 52% gain in the past month that has completely transformed the stock's character.
The driver of that reset is the earnings print from August 5–6. The stock leapt roughly 27% on the day and extended to a five-day gain of nearly 36% in the immediate aftermath. That single event absorbed most of the year's negativity in one session. The stock now trades at $12.35, a level that puts it squarely in recovery territory after a prolonged period of balance-sheet-driven pressure. The next scheduled earnings date is November 4, leaving the market three months to reprice the new reality.
Options positioning captures the mood precisely — this is now a call-dominated tape. The put/call ratio has collapsed to 0.14, well below its 20-day average of 0.32 and approaching the 52-week low of 0.07. A month ago the ratio was running above 0.60. The swing represents a near-complete reversal in how options traders are leaning: protection demand has evaporated and call interest dominates. Short interest tells a consistent story. At 2.0% of the free float, it is both small and shrinking — down roughly 16% over the past week and 21% over the past month. Borrowing costs are negligible at 0.72%, and availability is effectively unlimited, meaning there is no mechanical squeeze pressure in the lending market. Short sellers are not pressing this one.
The Street's positioning is harder to read clearly, as the most recent analyst data is stale — the last documented action was a Stifel upgrade to Buy (with a $10 target) in March 2025, a level the stock has now blown well past at $12.35. The mean analyst price target of $21 implies meaningful further upside from here, but that figure predates the earnings catalyst and should be treated with caution until updated coverage arrives. On valuation, the picture remains inexpensive: the EV/EBITDA multiple runs near 6.3x and the P/E near 8.4x, both consistent with a name the market has historically undervalued. The dividend score ranks in the 95th percentile, though the dividend itself has not been paid since mid-2022 — a legacy figure that flatters the factor score but reflects the old business structure under the Schweitzer-Mauduit name.
Institutional flows add a layer of nuance. American Century lifted its holding by 388,000 shares in the most recent reported period, and Dimensional Fund Advisors added 276,000 — both moves suggesting systematic value buyers were accumulating into weakness before the earnings pop. Arrowstreet Capital added 628,000 shares, the largest single increment among the top 15 holders. BlackRock, the largest holder at 11.2% of shares, added a more modest 173,000. The pattern looks like value and quant buyers building positions ahead of a catalyst, not momentum chasers arriving after.
Among US-listed peers, AVNT gained 2.7% on the week while FUL fell nearly 5% and RPM slipped 3.4% — suggesting specialty chemicals broadly had a mixed week and MATV's 2.3% weekly gain was earned on its own merits rather than a sector tailwind. The ORTEX short score has eased to 31.3, its lowest reading in the recent history, reflecting the combined effect of falling short interest and loosening borrow conditions.
What to watch next: whether the analyst community updates coverage with post-earnings targets — and whether new price targets land closer to the pre-existing $21 consensus or materially above the current $12.35 handle — will shape how the market calibrates the next move into the November earnings date.
See the live data behind this article on ORTEX.
Open MATV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
